Chart that shows adults how frequently they need to get certain vaccines.
Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2018–2019
The National Advisory Committee on Immunization (NACI): Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2018–2019 updates NACI’s recommendations regarding the use of seasonal influenza vaccines.
This strategy is grounded in several communications guiding principles: putting the health of Canadians first; providing timely and sound information; communicating in a coordinated fashion from across all levels of government; protecting confidentiality; and monitoring and adapting to the public’s perception of risk. The Annex outlines a risk communications approach, proposes triggers for action based on pandemics of varying impact, and includes a Communication Protocol that will be used countrywide in the event of a pandemic.
Chapitre sur la grippe du Guide canadien d’immunisation et Déclaration sur la vaccination antigrippale pour la saison 2018–2019
Le présent document, intitulé Comité consultatif national de l’immunisation (CCNI) : Chapitre sur la grippe du Guide canadien d’immunisation et Déclaration sur la vaccination antigrippale pour la saison 2018-2019, met à jour les recommandations du CCNI concernant l’utilisation de vaccins antigrippaux saisonniers.
Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials
An adjuvanted herpes zoster (HZ) subunit vaccine, HZ/su, demonstrated high efficacy against HZ and postherpetic neuralgia (PHN) in two randomized, observer-blind, placebo-controlled trials in adults aged >50 and >70 years (ZOE-50 and ZOE-70, respectively). Data from ZOE-50 and ZOE-70 trials were analyzed to evaluate the efficacy of HZ/su against
mortality, hospitalizations, and non-PHN complications of HZ including HZ-associated vasculitis, stroke, and disseminated, ophthalmic, neurologic, and visceral diseases.
Provides students with a list of credible online resources about immunization.
The immunization of immunocompromised children requires vaccination strategies that provide maximum protection with minimal harm. Responsibility for immunization is shared by their primary care providers and their specialists. Detailed guidelines are published in the current version of the Canadian Immunization Guide, and general principles are outlined in the CPS Practice Point document.
Intranasal influenza vaccine: Why does Canada have different recommendations from the USA on its use?
Canada and the USA differ in their recommendations for the use of live attenuated influenza vaccine (LAIV). The Canadian National Advisory Committee on Immunization (NACI) continues to recommend LAIV as one of the influenza vaccines available for use in children 2 to 17 years of age. The US Advisory Committee on Immunization Practices made an interim recommendation against the use of LAIV for the 2016-2017 influenza season in response to low LAIV effectiveness observed in the USA during the 2013-2014 to 2015-2016 seasons. The recommendation has been continued for the 2017-2018 season. In response, NACI undertook a review of available LAIV effectiveness data in children and adolescents from Canada, the USA and a number of European countries. This commentary by Canada’s Chief Public Health Officer summarizes the findings of that review and provides the rationale for Canada’s current continued recommendation for LAIV use.